Mymetics Corporation announced that the PATH Malaria Vaccine Initiative (MVI) has chosen Mymetics to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate. MVI is a global program whose objective is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries.
Mymetics’ proprietary virosome technology platform and its specialist virosome know-how has been selected to develop an innovative Malaria transmission-blocking vaccine candidate in partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
These new virosome vaccine candidates will each incorporate two different malaria parasite proteins supplied by LMIV and will be then separately tested in animal studies.
The project will start in November 2014, and preclinical results are expected by early 2016.